3 citations
,
June 2023 in “Journal of cosmetic dermatology” This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” This research found that combining a 308-nm excimer laser with oral compound glycyrrhizin and topical 0.03% tacrolimus was more effective for treating pediatric facial and cervical vitiligo, resulting in faster and higher rates of repigmentation with minimal adverse effects compared to glycyrrhizin and tacrolimus alone.
September 2022 in “The American journal of dermatopathology/American journal of dermatopathology” This case report highlights that lipedematous scalp and alopecia areata may coexist and that precise diagnosis requires histopathologic examination.
February 2022 in “Chinese Journal of Dermatology” This report presents a case of cicatricial female pattern hair loss in a 36-year-old woman, treated with topical minoxidil, tacrolimus, clobetasol, and oral medications, resulting in stabilized hair loss over six months.
52 citations
,
January 2016 in “Brazilian Journal of Medical and Biological Research” In this study, patients with generalized vitiligo treated with a combination of oral compound glycyrrhizin and UVB light showed the most effective repigmentation and disease stabilization compared to other treatment groups.